Logistic regression analysis of definitive treatment predictors in the study population
| . | OR (CI 95%) . | P . |
|---|---|---|
| GD1-APS | — | .063 |
| GD2-APS | — | 1 |
| Isolated GD | 10.743 (1.484-77.760) | .019 |
| Sex | 1.209 (0.224-6.533) | .825 |
| Age at GD onset, years | 1.018 (0.972-1.065) | .451 |
| fT4, ng/L | 1.029 (0.972-1.089) | .325 |
| fT3, ng/L | 1.016 (0.887-1.163) | .819 |
| TRAb, UI/mL | 1.054 (0.983-1.129) | .138 |
| Thyroid volume | 3.447 (0.757-18.142) | .160 |
| Immunosuppressive therapy | 0.225 (0.012-4.270) | .320 |
| . | OR (CI 95%) . | P . |
|---|---|---|
| GD1-APS | — | .063 |
| GD2-APS | — | 1 |
| Isolated GD | 10.743 (1.484-77.760) | .019 |
| Sex | 1.209 (0.224-6.533) | .825 |
| Age at GD onset, years | 1.018 (0.972-1.065) | .451 |
| fT4, ng/L | 1.029 (0.972-1.089) | .325 |
| fT3, ng/L | 1.016 (0.887-1.163) | .819 |
| TRAb, UI/mL | 1.054 (0.983-1.129) | .138 |
| Thyroid volume | 3.447 (0.757-18.142) | .160 |
| Immunosuppressive therapy | 0.225 (0.012-4.270) | .320 |
Abbreviations: fT4, free thyroxine (normal value 9.3-17.0 ng/L); fT3, free triiodothyronine (normal value 2.0-4.4 ng/L); GD, Graves disease; GD1-APS, patients with GD who developed APS; GD2-APS, patients with APS who developed GD; OR, odds ratio; TRAb, autoantibodies to the thyrotropin receptor (normal value <1.8 UI/mL).
Logistic regression analysis of definitive treatment predictors in the study population
| . | OR (CI 95%) . | P . |
|---|---|---|
| GD1-APS | — | .063 |
| GD2-APS | — | 1 |
| Isolated GD | 10.743 (1.484-77.760) | .019 |
| Sex | 1.209 (0.224-6.533) | .825 |
| Age at GD onset, years | 1.018 (0.972-1.065) | .451 |
| fT4, ng/L | 1.029 (0.972-1.089) | .325 |
| fT3, ng/L | 1.016 (0.887-1.163) | .819 |
| TRAb, UI/mL | 1.054 (0.983-1.129) | .138 |
| Thyroid volume | 3.447 (0.757-18.142) | .160 |
| Immunosuppressive therapy | 0.225 (0.012-4.270) | .320 |
| . | OR (CI 95%) . | P . |
|---|---|---|
| GD1-APS | — | .063 |
| GD2-APS | — | 1 |
| Isolated GD | 10.743 (1.484-77.760) | .019 |
| Sex | 1.209 (0.224-6.533) | .825 |
| Age at GD onset, years | 1.018 (0.972-1.065) | .451 |
| fT4, ng/L | 1.029 (0.972-1.089) | .325 |
| fT3, ng/L | 1.016 (0.887-1.163) | .819 |
| TRAb, UI/mL | 1.054 (0.983-1.129) | .138 |
| Thyroid volume | 3.447 (0.757-18.142) | .160 |
| Immunosuppressive therapy | 0.225 (0.012-4.270) | .320 |
Abbreviations: fT4, free thyroxine (normal value 9.3-17.0 ng/L); fT3, free triiodothyronine (normal value 2.0-4.4 ng/L); GD, Graves disease; GD1-APS, patients with GD who developed APS; GD2-APS, patients with APS who developed GD; OR, odds ratio; TRAb, autoantibodies to the thyrotropin receptor (normal value <1.8 UI/mL).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
